Monashee Investment Management LLC Acquires New Position in Zura Bio Limited (NASDAQ:ZURA)

Monashee Investment Management LLC purchased a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) in the second quarter, according to its most recent filing with the SEC. The firm purchased 240,000 shares of the company’s stock, valued at approximately $1,968,000. Monashee Investment Management LLC owned 0.89% of Zura Bio at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Zura Bio in the second quarter valued at $598,000. Raymond James & Associates purchased a new position in Zura Bio during the 2nd quarter valued at about $557,000. Finally, American International Group Inc. acquired a new position in Zura Bio during the second quarter worth about $30,000.

Zura Bio Stock Up 5.0 %

Shares of NASDAQ:ZURA traded up $0.21 during trading on Monday, reaching $4.44. 24,269 shares of the stock were exchanged, compared to its average volume of 325,656. The firm’s 50-day moving average price is $5.69 and its 200 day moving average price is $6.50. Zura Bio Limited has a 12-month low of $3.91 and a 12-month high of $37.55.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Equities analysts forecast that Zura Bio Limited will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

ZURA has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating on shares of Zura Bio in a research note on Thursday, August 17th. Raymond James raised their price objective on Zura Bio from $20.00 to $22.00 and gave the stock a “strong-buy” rating in a report on Tuesday, August 15th. LADENBURG THALM/SH SH started coverage on Zura Bio in a research note on Tuesday, October 10th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Oppenheimer initiated coverage on shares of Zura Bio in a research note on Thursday, August 24th. They set an “outperform” rating and a $17.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.60.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.